Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19293960 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | August 2025 | February 2026 | Allow | 6 | 0 | 1 | No | No |
| 19274255 | TRICYCLIC DERIVATIVES AND RELATED USES | July 2025 | January 2026 | Allow | 6 | 0 | 1 | Yes | No |
| 19237389 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | June 2025 | February 2026 | Abandon | 8 | 1 | 0 | No | No |
| 18960975 | HERBICIDAL AND PESTICIDAL COMPOSITIONS AND METHODS OF USE THEREOF | November 2024 | October 2025 | Abandon | 11 | 1 | 1 | No | No |
| 18901359 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | September 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18770514 | READY-TO-USE KETAMINE PREMIX FORMULATION | July 2024 | March 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18721770 | DRUG COMBINATION FOR TREATMENT OF GASTRIC CANCER | June 2024 | April 2025 | Allow | 10 | 2 | 0 | No | No |
| 18740610 | METHODS RELATED TO OPIOID THERAPEUTICS | June 2024 | January 2025 | Allow | 7 | 0 | 0 | No | No |
| 18736166 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | June 2024 | September 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18658460 | 1-(4-CARBONOIMIDOYLPHENOXY)-3-{4-[(E)-(PHENYLIMINO)METHYL]PHENOXY}PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | May 2024 | August 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18642074 | NOVEL THERAPY | April 2024 | July 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18635779 | CONTROLLED RELEASE FORMULATION AND MINIMALLY INVASIVE METHOD OF ADMINISTRATION | April 2024 | July 2024 | Allow | 3 | 1 | 0 | No | No |
| 18629507 | HUMAN THERAPEUTIC AGENTS | April 2024 | June 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18624045 | (2E)-4-[(4-CHLOROPHENYL)AMINO]-N-PHENYL-2-(PHENYLIMINO)-1,3,5-DIOXAZEPINE-7-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | April 2024 | June 2024 | Allow | 2 | 0 | 0 | No | No |
| 18430527 | 1-(2-HYDROXYBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUND | February 2024 | April 2024 | Allow | 2 | 0 | 0 | No | No |
| 18428252 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | January 2024 | January 2026 | Abandon | 24 | 2 | 0 | No | No |
| 18423815 | COMBINATION THERAPY | January 2024 | September 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18418901 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | January 2024 | June 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18417794 | COMPOSITIONS COMPRISING UROLITHIN COMPOUNDS | January 2024 | September 2025 | Abandon | 20 | 2 | 0 | Yes | No |
| 18414316 | Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde Scavengers | January 2024 | May 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18404283 | 1-(4-CARBONOIMIDOYLPHENOXY)-3-{4-[(E)-(PHENYLIMINO)METHYL]PHENOXY}PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | January 2024 | April 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18397710 | (2E)-4-[(4-CHLOROPHENYL)AMINO]-N-PHENYL-2-(PHENYLIMINO)-1,3,5-DIOXAZEPINE-7-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | December 2023 | March 2024 | Allow | 2 | 0 | 1 | Yes | No |
| 18396955 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF OPIOID AND OPIOID-LIKE DRUG ADDICTION | December 2023 | October 2025 | Abandon | 21 | 2 | 0 | No | No |
| 18521768 | METHODS AND COMPOSITIONS FOR REDUCING TOLERANCE TO OPIOID ANALGESICS USING IBOGAINE AND DERIVATIVES THEREOF | November 2023 | May 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18518044 | MEDIUM CHAIN TRIGLYCERIDE COMPOSITIONS | November 2023 | November 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18492536 | BETULIN-CONTAINING BIRCH BARK EXTRACTS AND THEIR FORMULATION | October 2023 | December 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18492750 | METHODS OF ADMINISTERING A PHARMACEUTICALLY ACCEPTABLE SALT OF 2-{[3,5-BIS(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}-4-CHLOROPHENYL DIHYDROGEN PHOSPHATE | October 2023 | August 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18492713 | 1-(2-HYDROXYBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18479338 | PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | October 2023 | January 2026 | Allow | 27 | 3 | 0 | No | Yes |
| 18374215 | METHOTREXATE FORMULATION | September 2023 | February 2026 | Allow | 28 | 3 | 0 | Yes | Yes |
| 18373838 | Methods and Compositions for Preventing and Treating Auditory Dysfunctions | September 2023 | February 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18367560 | METHODS AND COMPOSITIONS FOR REDUCING TOLERANCE TO OPIOID ANALGESICS USING IBOGAINE AND DERIVATIVES THEREOF | September 2023 | April 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18466226 | SUSTAINED-RELEASE ANESTHETIC COMPOSITIONS AND METHODS OF PREPARATION THEREOF | September 2023 | December 2024 | Allow | 15 | 0 | 0 | Yes | No |
| 18243572 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | September 2023 | March 2025 | Allow | 19 | 0 | 1 | Yes | No |
| 18232599 | Ifetroban Treatment for Systemic Sclerosis | August 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18366414 | CONTROLLED RELEASE FORMULATION AND MINIMALLY INVASIVE METHOD OF ADMINISTRATION TO LOCALLY TREAT CANCER | August 2023 | March 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18363961 | PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL-CONTAINING PHARMACEUTICAL COMPOSITION | August 2023 | March 2026 | Allow | 31 | 3 | 0 | Yes | Yes |
| 18353251 | COMPLEXES COMPRISING COLLAGEN PEPTIDES AND CURCUMINOIDS AND COMPOSITIONS THEREOF | July 2023 | April 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18221235 | METHODS FOR TREATING ATRIAL FIBRILLATIONS | July 2023 | June 2025 | Abandon | 24 | 4 | 0 | Yes | No |
| 18219783 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) | July 2023 | September 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18196889 | PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE | May 2023 | October 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18315954 | PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONIST | May 2023 | May 2025 | Allow | 24 | 1 | 1 | No | No |
| 18312857 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | May 2023 | August 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18139916 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | April 2023 | March 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18135847 | 3-HYDROXYBUTYRATE ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF CRITICAL CARE TREATMENT | April 2023 | May 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18135823 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY | April 2023 | May 2024 | Abandon | 13 | 2 | 0 | Yes | No |
| 18296290 | FORMULATIONS OF BENDAMUSTINE | April 2023 | March 2025 | Abandon | 23 | 2 | 0 | No | Yes |
| 18296268 | FORMULATIONS OF BENDAMUSTINE | April 2023 | September 2025 | Abandon | 30 | 3 | 0 | No | Yes |
| 18127612 | FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER | March 2023 | July 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18245583 | COMPOSITION FOR PROMOTING THE SKIN MICROBIOME | March 2023 | June 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18117899 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY | March 2023 | July 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18108423 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | February 2023 | April 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18093940 | NON-HORMONAL COMPOSITIONS AND METHODS FOR MALE CONTRACEPTION | January 2023 | February 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18068263 | TREATMENT OF CANCER/INHIBITION OF METASTASIS | December 2022 | September 2025 | Allow | 33 | 3 | 0 | No | No |
| 17926401 | PROPOFOL FOR DIAGNOSIS OF PRIMARY HEADACHE | November 2022 | December 2025 | Abandon | 37 | 1 | 0 | Yes | No |
| 17971033 | MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER | October 2022 | December 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17959350 | Combination Therapy | October 2022 | August 2024 | Allow | 22 | 2 | 0 | Yes | Yes |
| 17955712 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | September 2022 | September 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17934333 | METHOD AND COMPOSITIONS FOR THE TREATMENT OF ANEMIA THROUGH THE INHIBITION OF FURIN | September 2022 | September 2024 | Allow | 24 | 0 | 1 | Yes | No |
| 17913490 | N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | September 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 17906389 | RENAL FUNCTION PROTECTIVE AGENT | September 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17940803 | GLYCINE RECEPTOR MODULATORS AND METHODS OF USE | September 2022 | September 2024 | Allow | 24 | 0 | 1 | No | No |
| 17908876 | NAPHTHOQUINONE-BASED CHALCONE DERIVATIVES AND USES THEREOF | September 2022 | February 2026 | Allow | 41 | 0 | 1 | Yes | No |
| 17895946 | USE AND COMPOSITION FOR PROTECTION AGAINST ORGANOPHOSPHORUS POISONING | August 2022 | April 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17894604 | COMPOUNDS, PHARMACEUTICAL FORMULATIONS, AND METHODS FOR TREATMENT OF CANCER | August 2022 | August 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17892948 | COMPOSITIONS AND METHODS FOR TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS | August 2022 | February 2026 | Allow | 42 | 1 | 1 | Yes | No |
| 17821379 | TRPA1 ANTAGONIST FOR THE TREATMENT OF PAIN ASSOCIATED TO DIABETIC NEUROPATHIC PAIN | August 2022 | June 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17904587 | ANTI-RNA VIRUS DRUG AND APPLICATION THEREOF | August 2022 | November 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17820553 | STEROL DERIVATIVES AND PREPARATION METHOD AND USES THEREOF | August 2022 | February 2025 | Abandon | 30 | 3 | 0 | No | No |
| 17887777 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | August 2022 | December 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17884680 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES | August 2022 | August 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17884918 | PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE | August 2022 | March 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17884900 | PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE | August 2022 | April 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 17818667 | STEROL DERIVATIVES AND PREPARATION METHOD AND USES THEREOF | August 2022 | September 2023 | Allow | 13 | 0 | 0 | Yes | No |
| 17818302 | STEROL DERIVATIVES AND PREPARATION METHOD AND USES THEREOF | August 2022 | September 2023 | Allow | 13 | 0 | 0 | Yes | No |
| 17878984 | COMPOSITION FOR OPTIMIZED DIETARY SUPPLEMENT FORMULATIONS | August 2022 | January 2024 | Abandon | 17 | 0 | 1 | No | No |
| 17793998 | PESTICIDE COMPOSITIONS OF 1-PHENYL-TETRALIN DERIVATIVES | July 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17758839 | STRESS MANAGEMENT IN HUMAN SUBJECTS IN NEED THEREOF | July 2022 | December 2025 | Allow | 41 | 2 | 0 | No | No |
| 17758749 | COMPOSITIONS FOR ALLEVIATING THE SYMPTOMS OF LOW ANTERIOR RESECTION SYNDROME BY TOPICAL ADMINISTRATION TO THE NEORECTUM | July 2022 | October 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17792217 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS WITH ELAFIBRANOR | July 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17811802 | USE OF SENICAPOC FOR TREATMENT OF NEUROPATHIC PAIN | July 2022 | February 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17856549 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | July 2022 | November 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17852252 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | June 2022 | October 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17852265 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | June 2022 | October 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17809196 | COMPOSITIONS, METHODS, SYSTEMS AND/OR KITS FOR PREVENTING AND/OR TREATING NEOPLASMS | June 2022 | May 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17845961 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | June 2022 | September 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17842066 | Spironolactone Aqueous Compositions | June 2022 | June 2023 | Abandon | 12 | 2 | 0 | Yes | No |
| 17842102 | Spironolactone Aqueous Compositions | June 2022 | June 2023 | Abandon | 12 | 2 | 0 | Yes | No |
| 17841976 | CARBAMOYL PHENYLALANINOL ANALOGS AND USES THEREOF | June 2022 | October 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17838865 | COMPOUNDS FOR TREATING CUTANEOUS INFLAMMATION, FEMALE SEXUAL DISORDERS, AND IMPROVING SEXUAL FUNCTION | June 2022 | August 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17784554 | IMPROVED STABILITY INSECTICIDAL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | June 2022 | December 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17756978 | SOLID PHARMACEUTICAL PREPARATION | June 2022 | September 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17832838 | ANTIMICROBIAL COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF ACTIVATED CREATININE AND AN IMIDAZOLE ANTIFUNGAL AGENT | June 2022 | June 2024 | Allow | 24 | 3 | 0 | Yes | No |
| 17830957 | Method and Compositions for Treating Glioblastoma | June 2022 | September 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17827079 | METHODS FOR ALLEVIATING KIDNEY DISEASE AND FIBROSIS OF ORGAN | May 2022 | May 2024 | Allow | 24 | 1 | 1 | No | No |
| 17756534 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE | May 2022 | October 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17779787 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS | May 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17756437 | Z-STILBENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | May 2022 | June 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17746458 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | May 2022 | January 2026 | Abandon | 44 | 5 | 1 | No | No |
| 17755993 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | May 2022 | March 2026 | Abandon | 46 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner IVANOVA, SVETLANA M.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner IVANOVA, SVETLANA M works in Art Unit 1627 and has examined 904 patent applications in our dataset. With an allowance rate of 50.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner IVANOVA, SVETLANA M's allowance rate of 50.2% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by IVANOVA, SVETLANA M receive 1.74 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by IVANOVA, SVETLANA M is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +57.7% benefit to allowance rate for applications examined by IVANOVA, SVETLANA M. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.8% of applications are subsequently allowed. This success rate is in the 21% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.1% of cases where such amendments are filed. This entry rate is in the 35% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 34.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 58.0% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 48.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 60.7% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 56% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.